Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Taiwan Liposome, Novartis sales and marketing update

On Dec. 18, 2013, Taiwan Liposome granted Novartis' Sandoz AG generics unit rights to commercialize AmBiL amphotericin

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE